Securities and Exchange Commission
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 27, 1998
Biogen, Inc.
(Exact name of Registrant as specified in its charter)
Massachusetts 0-12042 04-3002117
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
14 Cambridge Center
Cambridge, MA 02142
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 679-2000
Item 9 Sale of Equity Securities Pursuant to Regulation S
On March 27, 1998, the Registrant issued an aggregate of 3,350 shares of
its Common Stock, $.01 par value per share, to thirteen employees of one of
its European distributors of AVONEX (registered trademark) (Interferon Beta
1a)in connection with the achievement by the distributor of certain
performance goals. The issuance of the shares was made in reliance on the
provisions of Regulation S of the Securities Act of 1933. Each of the persons
who received shares made a representation to the Registrant that he or she is
not a "U.S. person" as defined under Rule 902 of Regulation S.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Biogen, Inc.
By: /s/ Michael J. Astrue
Michael J. Astrue
Vice President - General Counsel
Date: March 30, 1998
